Pharmafile Logo
Pharmafocus logo
Advanced Search

BMS

Showing 15 posts of 286 posts found.

ASCO image

ASCO 2015 roundup: immuno-oncology hits its stride

June 8, 2015
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ASCO, BMS, CLL, pdl1

One year can make all the difference. The 2014 American Society of Clinical Oncology (ASCO) meeting took place just weeks …

Feature
yervoy image

BMS immunotherapy combination impresses at ASCO

June 1, 2015
Research and Development, Sales and Marketing ASCO, BMS, Yervoy, opdivo

Bristol-Myers Squibb has presented data showing that a combination of its immunotherapies Opdivo and Yervoy significantly increases survival in advanced …

News
Opdivo

BMS’ Opdivo improves lung cancer survival

May 29, 2015
Research and Development, Sales and Marketing ASCO, BMS, Bristol-Myers Squibb, NSCLC, lung cancer, nivolumab, non-small cell lung cancer, opdivo

A Phase III trial of Bristol-Myers Squibb’s immunotherapy Opdivo has found it increases overall survival in people with a common …

News
EMA image

EMA recommends eight drugs for approval

May 22, 2015
Sales and Marketing Amgen, BMS, EMA, Janssen, Merck, keytruda

The EMA has recommended eight medicines for approval in a round of reviews, including four new cancer indications. Amgen’s Repatha …

News
Merck image

Merck to test Keytruda combinations

May 8, 2015
Sales and Marketing BMS, Daiichi Sankyo, Merck, Plexxikon, keytruda, pembrolizumab

Merck will be teaming up with Daiichi Sankyo’s subsidiary Plexxikon to investigate immunotherapy combinations in cancer. A collaborative clinical trial …

News
abilify_bms_otsuka

FDA waves through generic BMS antipsychotic

April 30, 2015
Manufacturing and Production, Sales and Marketing Alembic, BMS, FDA, Hetero and Torrent Pharmaceuticals, Teva

The FDA has approved four generic versions of Bristol-Myers Squibb’s top selling Abilify, an atypical antipsychotic drug approved to treat …

News
BMS image

BMS lifted by new products

April 28, 2015
Sales and Marketing BMS, NICE, Q1, eams, immuno-oncology and hepatitis C

New drugs have helped Bristol-Myers Squibb see a slight increase in sales for the first quarter of 2015. Total revenues …

News
Opdivo

EMA approves BMS’ Opdivo for advanced skin cancer

April 27, 2015
Sales and Marketing BMS, Bristol-Myers Squibb, EMA, Merck, Yervoy, ipilimumab, keytruda, melanoma, nivolumab, opdivo, pembrolizumab, skin cancer

Bristol-Myers Squibb has earned a recommendation from the EMA for its cancer immunotherapy treatment Opdivo as a monotherapy for patients …

News
BMS image

BMS enters gene therapy development deal

April 7, 2015
Research and Development BMS, Bristol-Myers Squibb, R&D, cardiovascular disease, cvd, heart disease, heart failure, uniQure

Bristol-Myers Squibb (BMS) has signed a multi-million dollar agreement with Amsterdam-based gene therapy firm uniQure to boost research into new …

News
Orencia image

BMS backs rheumatoid arthritis prevention trial

March 27, 2015
Sales and Marketing BMS, Bristol-Myers Squibb, Orencia, RA, abatacept, rheumatoid arthritis

Bristol-Myers Squibb is funding a £3 million trial of Orencia as a preventative treatment for rheumatoid arthritis. The study will …

News
Keytruda image

Merck’s Keytruda trial stopped early after beating BMS’ Yervoy on survival

March 25, 2015
Research and Development, Sales and Marketing BMS, Merck, Yervoy, ipilimumab, keytruda, pembrolizumab

A trial comparing two potential blockbuster cancer treatments has been stopped early, after Merck’s Keytruda beat BMS’ Yervoy in a …

News
BMS image

BMS resubmits hepatitis C drug

March 13, 2015
Sales and Marketing BMS, NDA, daclatasvir gilead, hepatitis C, sovaldi

Bristol-Myers Squibb has resubmitted its hepatitis C (HCV) treatment for FDA approval despite previously backing out, as it spots a …

News
Eliquis image

Anti-blood clotting drug Eliquis gets NICE nod

March 6, 2015
Sales and Marketing BMS, DVT, Eliquis, NICE, Pfizer, Pradaxa, apixaban, clotting

Bristol-Myers Squibb and Pfizer’s Eliquis for preventing blood clots has been shown the green light to treat venous thromboembolism (VTE), …

News
BMS image

BMS’ Opdivo wins US lung cancer race

March 5, 2015
Research and Development, Sales and Marketing BMS, Prostvac, biosciences, flexus, lung cancer, oncology, opdivo

The FDA has approved Bristol-Myers Squibb’s Opdivo (nivolumab) for the treatment of patients with metastatic squamous non-small cell lung cancer …

News
BMS image

BMS in $1.5 billion immuno-oncology expansion

February 24, 2015
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Rigel, flexus, immuno-oncology

Bristol-Myers Squibb has confirmed two major deals to enhance the company’s standing in the immuno-oncology field. The first agreement sees …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025